線維筋痛症治療薬市場：薬剤クラス別、流通チャネル別-2025-2030年の世界予測

線維筋痛症治療薬市場は、2023年に34億7,000万米ドルと評価され、2024年には36億7,000万米ドルに達すると予測され、CAGR 5.07％で成長し、2030年には49億1,000万米ドルに達すると予測されています。

線維筋痛症治療薬には、疲労、睡眠、気分の問題を伴う広範な筋骨格系の疼痛を特徴とする慢性疾患である線維筋痛症の症状管理を目的とした治療が含まれます。鎮痛薬、抗うつ薬、抗けいれん薬などの薬物療法や、認知行動療法、運動プログラム、代替療法などの非薬物療法も含まれます。線維筋痛症治療薬の必要性は、本疾患の有病率と患者のQOLへの影響に起因しており、治療に対する反応には個人差があるため、個別化医療のアプローチを重視しています。適用範囲は、症状の緩和や機能強化から患者の心理的幸福の改善まで多岐にわたる。最終用途の範囲は主に病院や疼痛管理専門センターなどのヘルスケア環境であり、医療指導の下での在宅療法の採用も増加しています。

市場の洞察によると、線維筋痛症の罹患率の上昇とその治療介入に関する認識が成長の原動力となっています。新規製剤の開発や、遠隔患者管理のための遠隔医療のようなデジタルヘルスツールの統合は、大きな潜在機会を提供します。しかし、市場は診断の複雑さ、治療レジメンに対する患者の非服従性、慢性的な薬物使用による副作用などの課題に直面しています。規制上のハードルや償還の問題がさらに成長を阻害しています。新たな機会を活かすには、個別化医療やデジタルヘルス統合のような患者中心のイノベーションに注力することが推奨されます。また、非侵襲的な治療法の調査は、技術の進歩と事業拡大の有望な分野です。

全体として、線維筋痛症治療薬市場には継続的なイノベーションが求められており、研究開発への多額の投資や、治療効果と患者体験を高めるための製薬企業とテクノロジー企業とのコラボレーションが行われています。課題はあるもの、従来の治療の枠組みを超えた包括的なケアソリューションの提供を目指し、適応戦略や患者参画イニシアチブを優先する利害関係者にとっては、この市場は大きな可能性を秘めています。効果的なコミュニケーションと教育キャンペーンは、ヘルスケアプロバイダーと患者双方への市場浸透と受容をさらに促進することができます。

市場力学：急速に進化する線維筋痛症治療薬市場の主要市場インサイトを公開

線維筋痛症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の線維筋痛症の有病率の増加
  • 線維筋痛症治療薬の原因および有効性を特定するための臨床試験数の増加
  • 疾患の早期診断・早期治療への傾斜
• 市場抑制要因
  • 線維筋痛症の治療に伴う高コスト
• 市場機会
  • 的を絞った効果的な線維筋痛症治療のための個別化医療の重視
  • 効率的な線維筋痛症治療薬開発のための継続的研究開発
• 市場の課題
  • 線維筋痛症の不正確な診断に関する懸念

ポーターのファイブフォース：線維筋痛症治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：線維筋痛症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、線維筋痛症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析線維筋痛症治療薬市場における競合情勢の把握

線維筋痛症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス線維筋痛症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、線維筋痛症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨線維筋痛症治療薬市場における成功への道筋を描く

線維筋痛症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 線維筋痛症の罹患率は世界中で増加している
    • 線維筋痛症治療薬の原因と有効性を判断するための臨床試験の増加
    • 病気の早期診断と治療への傾向
  • 抑制要因
    • 線維筋痛症の治療にかかる高額な費用
  • 機会
    • 線維筋痛症の標的を絞った効果的な治療のための個別化医療に重点を置く
    • 線維筋痛症の有効な治療薬の開発に向けた継続的な研究開発
  • 課題
    • 線維筋痛症の不正確な診断に関連する懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 線維筋痛症治療薬市場薬剤クラス別

• 抗うつ薬
• 抗てんかん薬
• 筋弛緩剤

第7章 線維筋痛症治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第8章 南北アメリカの線維筋痛症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第9章 アジア太平洋地域の線維筋痛症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第10章 欧州・中東・アフリカの線維筋痛症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第11章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• Amgen Inc.
• Amicus Therapeutics
• Astellas Pharma Inc
• AstraZeneca plc
• Bayer AG
• Biogen Inc.
• BioMarin Pharmaceutical Inc
• C.H. Boehringer Sohn AG & Co. KG
• Eli Lilly and Company
• Gilead Sciences, Inc.
• GlaxoSmithKline（GSK）
• Jazz Pharmaceuticals plc
• Johnson & Johnson Services, Inc.
• Kyowa Kirin Co, Ltd
• Merck & Co., Inc.
• Novartis AG
• Pfizer inc.
• Regeneron Pharmaceuticals, Inc.
• Roche Holding AG
• Sanofi S.A.
• Sarepta Therapeutics, Inc.
• Takeda Pharmaceutical Company
• Teva Pharmaceutical Industries Ltd.
• The Bristol-Myers Squibb Company
• Vertex Pharmaceuticals Incorporated
• Viatris inc.

LIST OF FIGURES

• FIGURE 1. FIBROMYALGIA THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 11. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 13. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 19. FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. FIBROMYALGIA THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. FIBROMYALGIA THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ANTIEPILEPTIC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY MUSCLE RELAXANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 16. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 17. AMERICAS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 18. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 19. ARGENTINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 20. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 21. BRAZIL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 23. CANADA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 24. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 25. MEXICO FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 28. UNITED STATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 29. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. ASIA-PACIFIC FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. AUSTRALIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 34. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 35. CHINA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 36. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 37. INDIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. INDONESIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 39. INDONESIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 40. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 41. JAPAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. MALAYSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. MALAYSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. PHILIPPINES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 45. PHILIPPINES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. SINGAPORE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. SINGAPORE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 48. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 49. SOUTH KOREA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 50. TAIWAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. TAIWAN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. THAILAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. THAILAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 54. VIETNAM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 55. VIETNAM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 57. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. EUROPE, MIDDLE EAST & AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. DENMARK FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 60. DENMARK FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. EGYPT FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. EGYPT FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 63. FINLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 64. FINLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 65. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 66. FRANCE FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. GERMANY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 69. ISRAEL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 70. ISRAEL FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 71. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. ITALY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. NETHERLANDS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. NETHERLANDS FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 75. NIGERIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 76. NIGERIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 77. NORWAY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 78. NORWAY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. POLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. POLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 81. QATAR FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 82. QATAR FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 83. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. RUSSIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. SAUDI ARABIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 86. SAUDI ARABIA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 87. SOUTH AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 88. SOUTH AFRICA FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. SPAIN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. SWEDEN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 92. SWEDEN FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 93. SWITZERLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 94. SWITZERLAND FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. TURKEY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. TURKEY FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 98. UNITED ARAB EMIRATES FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 99. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 100. UNITED KINGDOM FIBROMYALGIA THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. FIBROMYALGIA THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 102. FIBROMYALGIA THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Fibromyalgia Therapeutics Market was valued at USD 3.47 billion in 2023, expected to reach USD 3.67 billion in 2024, and is projected to grow at a CAGR of 5.07%, to USD 4.91 billion by 2030.

Fibromyalgia Therapeutics encompasses medical treatments aimed at managing the symptoms of fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, and mood issues. The scope includes pharmaceutical interventions, such as analgesics, antidepressants, and anticonvulsants, as well as non-pharmacological therapies like cognitive-behavioral therapy, physical exercise programs, and alternative remedies. The necessity for fibromyalgia therapeutics stems from the disorder's prevalence and its impact on patient quality of life, emphasizing personalized medicine approaches due to varied individual responses to treatments. Applications range from symptom relief and functional enhancement to improving patients' psychological well-being. The end-use scope primarily involves healthcare settings, such as hospitals and specialized pain-management centers, alongside increasing adoption of home-based therapies under medical guidance.

Market insights reveal that growth is driven by the rising incidences of fibromyalgia and awareness about its therapeutic interventions. The development of novel drug formulations and the integration of digital health tools like telemedicine for remote patient management offer significant potential opportunities. However, the market faces challenges such as diagnosis complexities, patient non-adherence to treatment regimens, and side effects of chronic medication usage. Regulatory hurdles and reimbursement issues further inhibit growth. To capitalize on emerging opportunities, focusing on patient-centric innovations like personalized medicine and digital health integration is recommended. Additionally, research into non-invasive therapeutic modalities represents a promising area for technological advancement and business expansion.

Overall, the fibromyalgia therapeutics market demands continuous innovation, with substantial investment in R&D and collaboration between pharmaceutical companies and technology firms to enhance treatment efficacy and patient experience. Despite challenges, the market holds substantial promise for stakeholders who prioritize adaptive strategies and patient engagement initiatives, aiming to deliver comprehensive care solutions that transcend traditional therapeutic frameworks. Effective communication and education campaigns can further facilitate market penetration and acceptance among healthcare providers and patients alike.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Fibromyalgia Therapeutics Market

The Fibromyalgia Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of fibromyalgia worldwide
  • Rise in the number of clinical trials to determine causes and efficacy of fibromyalgia therapeutics
  • Inclination toward early diagnosis and treatment of diseases
• Market Restraints
  • High cost associated with fibromyalgia treatment
• Market Opportunities
  • Emphasis on personalized medicine for targeted and effective fibromyalgia therapies
  • Ongoing R&D for the development of efficient drugs for fibromyalgia
• Market Challenges
  • Concerns associated with inaccurate diagnosis of fibromyalgia

Porter's Five Forces: A Strategic Tool for Navigating the Fibromyalgia Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Fibromyalgia Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Fibromyalgia Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Fibromyalgia Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Fibromyalgia Therapeutics Market

A detailed market share analysis in the Fibromyalgia Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Fibromyalgia Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Fibromyalgia Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Fibromyalgia Therapeutics Market

A strategic analysis of the Fibromyalgia Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Fibromyalgia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Amicus Therapeutics, Astellas Pharma Inc, AstraZeneca plc, Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, Gilead Sciences, Inc., GlaxoSmithKline (GSK), Jazz Pharmaceuticals plc, Johnson & Johnson Services, Inc., Kyowa Kirin Co, Ltd, Merck & Co., Inc., Novartis AG, Pfizer inc., Regeneron Pharmaceuticals, Inc., Roche Holding AG, Sanofi S.A., Sarepta Therapeutics, Inc., Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Ltd., The Bristol-Myers Squibb Company, Vertex Pharmaceuticals Incorporated, and Viatris inc..

Market Segmentation & Coverage

This research report categorizes the Fibromyalgia Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Antidepressants, Antiepileptic, and Muscle Relaxants.
• Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of fibromyalgia worldwide
    • 5.1.1.2. Rise in the number of clinical trials to determine causes and efficacy of fibromyalgia therapeutics
    • 5.1.1.3. Inclination toward early diagnosis and treatment of diseases
  • 5.1.2. Restraints
    • 5.1.2.1. High cost associated with fibromyalgia treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Emphasis on personalized medicine for targeted and effective fibromyalgia therapies
    • 5.1.3.2. Ongoing R&D for the development of efficient drugs for fibromyalgia
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with inaccurate diagnosis of fibromyalgia
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Fibromyalgia Therapeutics Market, by Drug Class

• 6.1. Introduction
• 6.2. Antidepressants
• 6.3. Antiepileptic
• 6.4. Muscle Relaxants

7. Fibromyalgia Therapeutics Market, by Distribution Channel

• 7.1. Introduction
• 7.2. Hospital Pharmacy
• 7.3. Online Pharmacy
• 7.4. Retail Pharmacy

8. Americas Fibromyalgia Therapeutics Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Fibromyalgia Therapeutics Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Fibromyalgia Therapeutics Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. Market Share Analysis, 2023
• 11.2. FPNV Positioning Matrix, 2023
• 11.3. Competitive Scenario Analysis
• 11.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. Amgen Inc.
• 3. Amicus Therapeutics
• 4. Astellas Pharma Inc
• 5. AstraZeneca plc
• 6. Bayer AG
• 7. Biogen Inc.
• 8. BioMarin Pharmaceutical Inc
• 9. C.H. Boehringer Sohn AG & Co. KG
• 10. Eli Lilly and Company
• 11. Gilead Sciences, Inc.
• 12. GlaxoSmithKline (GSK)
• 13. Jazz Pharmaceuticals plc
• 14. Johnson & Johnson Services, Inc.
• 15. Kyowa Kirin Co, Ltd
• 16. Merck & Co., Inc.
• 17. Novartis AG
• 18. Pfizer inc.
• 19. Regeneron Pharmaceuticals, Inc.
• 20. Roche Holding AG
• 21. Sanofi S.A.
• 22. Sarepta Therapeutics, Inc.
• 23. Takeda Pharmaceutical Company
• 24. Teva Pharmaceutical Industries Ltd.
• 25. The Bristol-Myers Squibb Company
• 26. Vertex Pharmaceuticals Incorporated
• 27. Viatris inc.